Ascorbic acid inhibits antitumor activity of bortezomib in vivo

Antioxidants block proteasome inhibitor function in endometrial carcinoma cells

(2009) David Llobet et al.   ANTI-CANCER DRUGS

Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment

(2009) Z. Lin et al.   CLINICAL CANCER RESEARCH

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

(2008) L. J. Hoffer et al.   ANNALS OF ONCOLOGY

Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib

(2008) F.-T. Liu et al.   BLOOD

Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib

(2008) Silvia Nerini-Molteni et al.   BRITISH JOURNAL OF HAEMATOLOGY

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

(2008) Pieter Sonneveld et al.   CANCER

Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs

(2008) M. L. Heaney et al.   CANCER RESEARCH

Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?

(2008) B. D. Lawenda et al.   JNCI-Journal of the National Cancer Institute

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE